Joan Walker to Prospective Studies
This is a "connection" page, showing publications Joan Walker has written about Prospective Studies.
Connection Strength
0.420
-
Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol. 2012 Mar 01; 30(7):695-700.
Score: 0.076
-
Predicting absolute risk of CIN3 during post-colposcopic follow-up: results from the ASCUS-LSIL Triage Study (ALTS). Am J Obstet Gynecol. 2006 Aug; 195(2):341-8.
Score: 0.052
-
Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study. Gynecol Oncol. 2021 11; 163(2):392-397.
Score: 0.037
-
Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study. Gynecol Oncol. 2021 05; 161(2):512-515.
Score: 0.036
-
GOG 244 - The Lymphedema and Gynecologic cancer (LeG) study: The impact of lower-extremity lymphedema on quality of life, psychological adjustment, physical disability, and function. Gynecol Oncol. 2021 01; 160(1):244-251.
Score: 0.035
-
Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study. Gynecol Oncol. 2020 01; 156(1):131-139.
Score: 0.033
-
Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 09; 146(3):477-483.
Score: 0.028
-
Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 04; 145(1):122-129.
Score: 0.027
-
Patient and physician factors associated with participation in cervical and uterine cancer trials: an NRG/GOG247 study. Gynecol Oncol. 2015 Jul; 138(1):101-8.
Score: 0.024
-
Phase II trial of vaginal cuff brachytherapy followed by chemotherapy in early stage endometrial cancer patients with high-intermediate risk factors. Gynecol Oncol. 2014 Jan; 132(1):50-4.
Score: 0.021
-
Gynecologic Oncology Group risk groups for vulvar carcinoma: improvement in survival in the modern era. Gynecol Oncol. 2007 Sep; 106(3):521-5.
Score: 0.014
-
Hormonal contraceptive use, pregnancy and parity, and the risk of cervical intraepithelial neoplasia 3 among oncogenic HPV DNA-positive women with equivocal or mildly abnormal cytology. Int J Cancer. 2005 Dec 20; 117(6):1007-12.
Score: 0.012
-
Outpatient implantation of a central venous access system in gynecologic oncology patients. J Reprod Med. 2003 Nov; 48(11):875-81.
Score: 0.011
-
Method and timing of tumor volume measurement for outcome prediction in cervical cancer using magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2002 Jan 01; 52(1):14-22.
Score: 0.009
-
Cost analysis of Hickman catheter insertion at bedside in gynecologic oncology patients. J Am Coll Surg. 1994 Nov; 179(5):558-60.
Score: 0.006